Correlation analysis between the pre‑operative contrast‑enhanced ultrasound parameters and biological characteristics of papillary thyroid carcinoma and associated risk factors for prognosis after radiofrequency ablation

Wang,Dawei; Zheng,Xuena; Li,Min

doi:10.3892/etm.2020.8845

Correlation analysis between the pre‑operative contrast‑enhanced ultrasound parameters and biological characteristics of papillary thyroid carcinoma and associated risk factors for prognosis after radiofrequency ablation

Authors:
- Dawei Wang
- Xuena Zheng
- Min Li
View Affiliations

Affiliations: Department of Ultrasound, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Hematology, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China, Department of Endocrinology and Rheumatology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: June 5, 2020 https://doi.org/10.3892/etm.2020.8845
Pages: 1575-1581
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the correlation between the contrast‑enhanced ultrasound (CEUS) parameters and biological characteristics of papillary thyroid carcinoma (PTC), and identify risk factors of recurrence for the prognosis after radiofrequency ablation. A total of 72 patients with PTC were included. Disease recurrence and metastasis were evaluated based on the imaging performance and laboratory tests. Perfusion parameters were recorded and compared. After biopsy, the tumor tissues were subjected to hematoxylin and eosin staining, and the expression levels of P53 and Ki67 were detected using immunohistochemistry. The association between the CEUS parameters and the expression of P53 and Ki67 was analyzed. Risk factors for disease recurrence were analyzed using logistic regression. Compared with normal tissues, PTC tissue was characterized by a slow perfusion pattern with no obvious enhancement. The peak time and intensity were lower, while the initial increasing time and mean transit time (MTT) were longer in the PTC tissue. The expression levels of P53 and Ki67 in PTC tissues were associated with age, local infiltration, lymph node metastasis and the number of lesions, but not with gender, tumor size, histological type or degree of differentiation. The initial increasing time, peak time and MTT were negatively correlated, while the peak intensity was positively correlated with the expression of P53 and Ki67 in PTC tissues. Multivariate logistic regression analysis suggested that lymph node metastasis, age, local infiltration, peak intensity and MTT were risk factors for disease recurrence. In conclusion, quantitative CEUS parameters are closely linked to the biological characteristics of PTC and may serve as indicators for the prognosis of patients.

View Figures

View References

1	He C, Zhang J and Xing Y: Research progress in diagnosis and treatment of papillary thyroid carcinoma. Modern Diagnosis Treat. 17:290–292. 2006.(In Chinese).
2	Fu D, Zhu Y, Shao W, et al: Clinical analysis of 124 cases of papillary microcarcinoma. Chin J Curr Adv Gen Surg. 16:157–158. 2013.(In Chinese).
3	Sun P and Liang D: Effects of ultrasound-guided radiofrequency ablation and postoperative stress on thyroid micropapillary carcinoma. Chin J Curr Adv Gen Surg. 21:217–222. 2018.
4	Zhou Q and Jiang Z: Value of Contrast-enhanced ultrasound in diagnosis of thyroid papillary carcinoma. Chin J Ultrasound Med. 27:595–597. 2011.
5	Wang F, Chen M, Huang Y, Gao Y, Qiu Y, Wang B and Chang C: Ultrasonograpbic characteristics of thyroid carcinoma and analysis of the misdiagnosed cases. Chin J Ultrasonography. 19:134–137. 2010.(In Chinese).
6	Gao X and Zhang Y, Sun Y and Zhang Y: Clinical efficacy and adverse reaction analysis of laparoscopic surgery for colon; cancer. Chin J Curr Adv Gen Surg. 18:738–740. 2015.(In Chinese).
7	Liu F, Xia Q, Qiu J, et al: Expression and clinical significance of C-myb and P53 in papillary thyroid carcinoma. J Oncol. 21:320–324. 2015.
8	Dong L, Peng T, Liu N, Shuang L and Xudong S: Expression and clinical significance of ER, PR and Her2/neu in papillary thyroid carcinoma. J Modern Oncol. 23:3576–3579. 2015.
9	Jiang WF, Wang YX and Cheng M: Expression and relationship of XIAP, P53 and Ki67 in papillary thyroid carcinoma. Beijing Med J. 34:971–974. 2012.(In Chinese).
10	Tang X, Cui D, Chi J, Wang Z, Wang T, Zhai B and Li P: Evaluation of the safety and efficacy of radiofrequency ablation for treating benign thyroid nodules. J Cancer. 8:754–760. 2017.PubMed/NCBI View Article : Google Scholar
11	Zhang L, Dong Y, Hu S, et al: The impact of American Cancer Joint Committee Revised Thyroid Cancer Staging System (8th edition) on staging of papillary thyroid carcinoma. Chin Oncol. 7:491–496. 2018.(In Chinese). PubMed/NCBI View Article : Google Scholar
12	Song J, Yang Z and Wang HM: Domestic progress in the diagnosis of differentiated thyroid carcinoma. World Latest Med Infor. 18:64–65. 2016.(In Chinese).
13	Xhaard C, Rubino C, Cléro E, Maillard S, Ren Y, Borson-Chazot F, Sassolas G, Schvartz C, Colonna M, Lacour B, et al: Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in young women in France: A population-based case-control study. Am J Epidemiol. 180:1007–1017. 2014.PubMed/NCBI View Article : Google Scholar
14	Tafani M, De Santis E, Coppola L, Perrone GA, Carnevale I, Russo A, Pucci B, Carpi A, Bizzarri M and Russo MA: Biodging hypoxin, inflammation and estrogen receptors in the thyroid cancer progression. Biomed Pharmacother. 68:1–5. 2014.PubMed/NCBI View Article : Google Scholar
15	Chen X and Zhao B: Contrast-enhanced ultrasound in diagnosis and treatment of liver diseases. Chin J Med Imaging Technol. 21:484–487. 2005.
16	Du L and Li F: Application of contrast-enhanced ultrasound in the diagnosis of renal occupied lesions. Chin J Ultrasonography. 15:813–815. 2006.
17	Wang L and Yang W: Expression and clinical significance of p53, C-myc and CerbB-2 in papillary thyroid carcinoma. Chongqing Med. 45:77–80. 2016.
18	Wang YQ and Qiu XG: Expressions of p53, RUNX3 and Ki67 proteins in papillary thyroid carcinoma and clinical significance. Clin Med. 33:3–4. 2013.
19	de Azambuja E and Cardoso F: Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12, 155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI View Article : Google Scholar
20	Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, et al: Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for Node-negative breast cancer. J Natl Cancer Inst. 100:207–212. 2008.PubMed/NCBI View Article : Google Scholar
21	Yeh CC, Lin JT, Jeng LB, Charalampos I, Chen TT, Lee TY, Wu MS, Kuo KN, Liu YY and Wu CY: Hepatic resection for hepatocellular carcinoma patients on hemodialysis for Uremia: A nationwide cohort study. World J Surg. 37:2402–2409. 2013.PubMed/NCBI View Article : Google Scholar
22	Argalia G, De Bernardis S, Mariani D, Abbattista T, Taccaliti A, Ricciardelli L, Faragona S, Gusella PM and Giuseppetti GM: Ultrasonographic contrast agent: Evaluation of time-intensity curves in the characterisation of solitary thyroid nodules. Radiol Med. 103:407–13. 2002.(In English, Italian). PubMed/NCBI
23	Shi X, Zheng X, Guo H, Li C, Peng M, Zhou G, Jiang Y, Yan S and Yu Y: Contrast analysis on contrast-enhanced ultrasonography and pathology of thyroid lumps. Zhejiang Practical Med. 12:87–88. 2007.(In Chinese).
24	Bartolotta TV, Midiri M, Galia M, Runza G, Attard M, Savoia G, Lagalla R and Cardinale AE: Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: Initial results. Eur Radiol. 16:2234–2241. 2006.PubMed/NCBI View Article : Google Scholar
25	Chen Q: Diagnostic value of high frequency ultrasound in benign and malignant thyroid nodules. Chin Imaging J Integrated Traditional Western Med. 10:545–546. 2012.
26	Zhao L, Lin J, Shi B, et al: Expression of P53, Ki67, galectin-3, HBME-1, 34βE12 and CK19 in papillary thyroid carcinoma and its clinicopathological significance. Basic Clin Med. 32:1202–1206. 2012.
27	Huang H: Expression of CK19, Ki67 and VEGF and their clinical significances in papillary thyroid carcinoma. J Nanchang Univ (Med Sci). 50:24–27. 2010.
28	Jia W and Yin C: Expressions of p53, Her-2 and Ki67 in thyroid papillary carcinoma and their clinical significance. China J Modern Med. 28:33–37. 2018.